ONCOLYTICS BIOTECH INC
ONCOLYTICS BIOTECH INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab on July 30, 2027. There are 2 upcoming events on record.
Cash runway is approximately 1.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 12 concluded trials, 83% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| July 30, 2027 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Trial Milestone | Phase 1/Phase 2 |
| August 30, 2027 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | Trial Milestone | Phase 2 |
Track ONCY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ONCY in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| October 14, 2026 | 8-K filed: Other event | Filing | — |
| October 13, 2026 | 8-K filed: Other event | Filing | — |
| September 29, 2026 | 8-K filed: Other event | Filing | — |
| September 28, 2026 | 8-K filed: Other event | Filing | — |
| September 10, 2026 | 8-K filed: Other event | Filing | — |
| August 18, 2026 | 8-K filed: Other event | Filing | — |
| July 24, 2026 | 8-K filed: Listing / standard notice | Corporate | — |
| July 20, 2026 | 8-K filed: Other event | Filing | — |
| July 13, 2026 | 8-K filed: Other event | Filing | — |
| June 16, 2026 | 8-K filed: Other event | Filing | — |
| June 2, 2026 | 8-K filed: Leadership change, Other event | Corporate | — |
| June 1, 2026 | 8-K filed: Other event | Filing | — |
| May 22, 2026 | 8-K filed: Other event | Filing | — |
| May 4, 2026 | 8-K filed: Other event | Filing | — |
| April 27, 2026 | 8-K filed: Other event | Filing | — |
| April 6, 2026 | 8-K filed: Other event | Filing | — |
| April 6, 2026 | 8-K filed: Other event | Filing | — |
| April 1, 2026 | 8-K filed: Material agreement, Leadership change, Other event | Corporate | — |
| March 19, 2026 | 8-K filed: Other event | Filing | — |
| March 2, 2026 | 8-K filed: Other event | Filing | — |
| February 24, 2026 | 8-K filed: Other event | Filing | — |
| February 4, 2026 | 8-K filed: Other event | Filing | — |
| January 15, 2026 | 8-K filed: Other event | Filing | — |
| January 12, 2026 | 8-K filed: Other event | Filing | — |
| January 7, 2026 | 6-K filed: Foreign issuer report | Filing | — |
| December 16, 2025 | 6-K filed: Foreign issuer report | Filing | — |
| December 10, 2025 | 6-K filed: Foreign issuer report | Filing | — |
| November 20, 2025 | 6-K filed: Foreign issuer report | Filing | — |
| November 19, 2025 | 6-K filed: Foreign issuer report | Filing | — |
| November 12, 2025 | 6-K filed: Foreign issuer report | Filing | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.